UniXell Bio

UniXell Bio is a South Korean biotechnology company specializing in the development of next-generation cell therapies using induced pluripotent stem cells (iPSCs). The company leverages its proprietary platform to differentiate iPSCs into high-purity functional cells, such as cardiomyocytes and chondrocytes, to treat chronic and degenerative diseases. Their primary focus areas include cardiovascular diseases, specifically heart failure, and musculoskeletal conditions like osteoarthritis. By utilizing universal cell technology and gene editing, UniXell Bio aims to overcome the limitations of traditional cell therapies, such as immune rejection and limited scalability. The company is currently advancing its lead programs through pre-clinical development with the goal of providing off-the-shelf regenerative medicine solutions.